Heart failure during and after pregnancy has quietly become one of the most complex frontiers in women's cardiovascular medicine — and the population at risk is expanding faster than clinical infrastructure can keep pace. As delayed childbearing pushes first pregnancies into the fifth decade of life, and as survivors of childhood cancer and congenital heart disease now routinely reach reproductive age, the overlap between cardiac vulnerability and pregnancy has grown into a distinct clinical crisis demanding specialized management frameworks.
This European Heart Failure Journal review maps the full spectrum of cardiovascular risk across the reproductive lifespan, with particular focus on heart failure as both a pre-existing condition and a pregnancy-triggered outcome. Four high-stakes clinical scenarios anchor the analysis: inherited cardiomyopathies, peripartum cardiomyopathy (PPCM), hypertensive disorders of pregnancy, and pregnancies formally classified as very high cardiac risk. The review emphasizes that genetic counseling and testing must now be integrated into cardio-obstetric decision-making at every stage — from pre-conception risk stratification through neonatal assessment — given the heritable nature of several cardiomyopathies and the therapeutic implications of identifying pathogenic variants before delivery. The discussion also addresses the ethically fraught territory of termination of pregnancy in women with life-threatening cardiac conditions.
The clinical significance here extends well beyond obstetrics. PPCM, for instance, remains incompletely understood mechanistically, with bromocriptine trials and prolactin-pathway hypotheses still evolving. Meanwhile, hypertensive disorders of pregnancy are increasingly recognized as long-term cardiovascular risk markers, not just acute obstetric emergencies. What this review underscores — and what health systems have been slow to operationalize — is that maternal cardiovascular mortality is a preventable tragedy when multidisciplinary cardio-obstetric teams are in place before complications emerge. The primary limitation of this work is its narrative review design; it synthesizes expert consensus rather than generating new causal evidence. Nevertheless, it serves as a timely clinical roadmap at a moment when maternal mortality from cardiovascular causes is rising across high-income countries.